期刊
AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 109, 期 7, 页码 950-966出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1038/ajg.2014.131
关键词
-
资金
- Boehringer Ingleheim
- Abbvie
- Aegerion
- Salix
- BMS
- Lilly
- Cumberland Pharmaceuticals
- Intercept Pharmaceuticals
- Gilead
- Galectin Pharmaceuticals
- Alnylam
- Clinuvel
- Merck
- US National Institutes of Health (NHLBI, NIDDK)
- Vertex
- Novartis
- Anadys
- BI
- Cumberland
- Ocera
Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction and it can lead to jaundice, liver failure, or even death. Antimicrobials and herbal and dietary supplements are among the most common therapeutic classes to cause DILI in the Western world. DILI is a diagnosis of exclusion and thus careful history taking and thorough work-up for competing etiologies are essential for its timely diagnosis. In this ACG Clinical Guideline, the authors present an evidence-based approach to diagnosis and management of DILI with special emphasis on DILI due to herbal and dietary supplements and DILI occurring in individuals with underlying liver disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据